Previous 10 | Next 10 |
SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications in which higher long-term returns are expected, given the promising data generated to date in refractory fungal infections, includi...
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that interim data from the Phase 3 FURI study of oral ibrexaf...
JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Off...
Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response (56%) or no disease progression (27%). Data from the ongoing Phase 3 CARES study will also be presented demonstrating positive outcomes of...
JERSEY CITY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will present posters at four upcoming U.S. and inter...
Summary SCYX has a commercial antifungal Brexafemme. However, we are neutral on its commercial potential as discussed in our previous article. No big pharma deal materialized, and the company raised USD45M through pre-funded warrant offerings. The drug's true upside is in syst...
SCYNEXIS, Inc. (SCYX) Q2 2022 Results Conference Call August 15, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications and IR Dr. Marco Taglietti - President and CEO Christine Coyne - Chief Commercial Officer Dr. David Angulo - Chief Medical ...
Scynexis ( NASDAQ: SCYX ) stock rose ~3% on Aug. 15 after Q2 revenue grew 29% Q/Q. Sales of vaginal yeast infection drug Brexafemme (ibrexafungerp tablets) increased to $1.3M in Q2, compared to $0.7M in Q1. "We are pleased to see the improvements to th...
SCYNEXIS press release ( NASDAQ: SCYX ): Q2 GAAP EPS of -$0.31 beats by $0.28 . Revenue of $1.32M misses by $0.32M . Cash and cash equivalents totaled $118.7 million on June 30, 2022, compared to $104.5 million in cash and cash equivalents on December 31, 2021....
BREXAFEMME ® (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million in Q2 2022, compared to $0.7 million in Q1. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand BREXAFEMME’s lab...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...